Sanofi invests €300 million in new Belgian biologics site
Sanofi has announced plans to expand its site in Geel, Belgium, with a €300 million investment to support its pipeline of monoclonal antibodies.
The existing facility will be adapt and expand production capabilities, as well as develop new laboratories focused on quality control and manufacturing sciences. This further investment builds on the €600 million already provided by Sanofi, and its speciality care global business unit Sanofi Genzyme, since industrial biotech activities began there in 2001.
The upgraded facility will add over 8000m2 of manufacturing space, increase overall production capacity and diversify to other drugs and therapeutic areas. Currently, the facility supports the global production of a protein therapy for rare muscular condition, Pompe disease.
Phillipe Luscan, president of Sanofi in France, says: “We have a robust development pipeline of biological molecules, including monoclonal antibodies, and this investment furthers our work and expertise in key disease areas such as cardiovascular disease, rheumatoid arthritis, and atopic dermatitis. This is an exciting opportunity for our site in Geel and we are very pleased with the support we received from the government of Flanders, the Flanders Investment and Trade, and the Flanders Entrepreneurship agency.”
This latest investment is said to form a key part of Sanofi’s plan to launch several new biologics in the coming years.
Sanofi and Regeneron have announced results from the second investigational phase 3 NOTUS trial for …
Novo Nordisk have announced plans to invest over 42bn Danish kroner to expand its existing …